Mankind Pharma Share Price Falls 4.89% After Q1 Results

July 31, 2026
Posted by: Ankit Jaiswal
Category: News

Mankind Pharma falls 4.89% to Rs 2,450.00. Q1 FY27 PAT Rs 568.06 crore vs Rs 438.32 crore (+29.6% YoY). Revenue Rs 4,030.59 crore vs Rs 3,570.35 crore (+12.9% YoY).

The Mankind Pharma share price fall after Q1 results theme was in focus on Friday, with Mankind Pharma shares moving 4.89% to Rs 2,450.00, from a previous close of Rs 2,575.90, after the company reported its results for the quarter ended June 2026.

Mankind Pharma reported a profit after tax of Rs 568.06 crore for Q1 FY27, against Rs 438.32 crore in the year-ago quarter, a change of +29.6%. Revenue for the quarter stood at Rs 4,030.59 crore, compared with Rs 3,570.35 crore a year earlier, a change of +12.9%.

Click Here – Get Free Investment Predictions

Table of Contents

Mankind Pharma Q1 FY27 Results: Key Numbers

Metric	Q1 FY27	Q1 FY26	YoY Change
Profit After Tax	Rs 568.06 crore	Rs 438.32 crore	+29.6%
Revenue	Rs 4,030.59 crore	Rs 3,570.35 crore	+12.9%

Why Mankind Pharma Shares Moved 4.89% Today

Check the Univest Screener for sector-linked stocks

Profit and revenue both grew strongly, though shares slipped as the market weighed a higher effective tax rate against the topline beat.

About Mankind Pharma

One of India’s largest pharmaceutical companies by volume, known for consumer healthcare and chronic therapy brands.

Download the Univest iOS App or Univest Android App to track Mankind Pharma’s stock price and quarterly results.

What to Watch Going Forward

Investors tracking Mankind Pharma should watch management commentary on demand trends, cost pressures and full-year guidance in the coming quarters, since forward-looking statements often matter as much as the headline quarterly numbers for how the stock trades over the following weeks.

Conclusion

The Mankind Pharma share price fall after Q1 results move reflects the market’s reaction to the company’s latest quarterly performance. Investors should evaluate the stock against its own growth trajectory and valuation, and consult a SEBI-registered financial advisor before making any investment decision.

Investors continuing to track the Mankind Pharma share price fall after Q1 results story should watch how the stock trades in the sessions ahead.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on Mankind pharma share price fall after q1 results

Why did Mankind Pharma share price fall after Q1 results?

Ans. Mankind Pharma shares moved 4.89% after the company reported Q1 FY27 profit after tax of Rs 568.06 crore, a change of +29.6% from Rs 438.32 crore a year earlier, on revenue of Rs 4,030.59 crore.

What was Mankind Pharma’s profit in Q1 FY27?

Ans. Mankind Pharma reported a profit after tax of Rs 568.06 crore for the quarter ended June 2026, compared with Rs 438.32 crore in the same quarter a year earlier.

What was Mankind Pharma’s revenue in Q1 FY27?

Ans. Mankind Pharma’s revenue for Q1 FY27 stood at Rs 4,030.59 crore, compared with Rs 3,570.35 crore a year earlier, a change of +12.9%.

What is Mankind Pharma’s current share price?

Ans. Mankind Pharma shares were trading at Rs 2,450.00 today, falling 4.89% from the previous close of Rs 2,575.90.

Should I buy Mankind Pharma shares after the Q1 results move?

Ans. Investment decisions should be based on individual research and risk appetite; consult a SEBI-registered financial advisor before buying or selling shares after any results-driven move.

Where can I track Mankind Pharma’s live share price?

Ans. Mankind Pharma’s live share price and quarterly result updates can be tracked on the Univest platform alongside SEBI-registered research.

Share Price Falls

Author: Ankit Jaiswal

Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.